The SLEEP 2022 conference poster revealed some of the interactions between idiopathic hypersomnia and various aspects of life, such as weight changes and interpersonal relationships.
Two posters at the SLEEP 2022 conference revealed some of the interactions between idiopathic hypersomnia and various aspects of life, such as weight changes and interpersonal relationships.
Effects of idiopathic hypersomnia on relationships
Idiopathic hypersomnia is a rare neuropathy characterized by hypersomnia that can be very debilitating for the patient. This condition often appears in adolescence and affects quality of life. In a recent study, researchers looked at how they can influence a patient’s social life, especially social, romantic, and sexual relationships, more than narcolepsy.1
The researchers enrolled 106 young adults aged 18 to 39 years with self-reported idiopathic hypersomnia. Participants completed an online survey to assess the impact on relationships and provider communication.
The average (SD) age of the participants was 29.6 (5.2) years, 90% of whom were female. In addition, 90% of the cohort was white and 80% were employed.
Overall, 98% of participants reported that idiopathic hypersomnia affected social life, and 92% said it was more difficult to establish new relationships. In addition, 89% said their condition affected their sexual life, and 32% said it led to the collapse of romantic relationships.
Participants reported receiving more support from important others compared to family and friends. Health professionals asked 34% and 9% of participants about the impact of idiopathic hypersomnia on social or sexual life, respectively. Researchers suggested that more clinicians should assess and further support the social health of young adults with idiopathic hypersomnia.
Effects of idiopathic hypersomnia treatment on body weight
Treatment of patients with narcolepsy with sodium oxybate (Xyrem) therapy is associated with weight loss. Compared to normal sodium oxybate, low sodium oxybate (Xywav) has the same level of active moiety with 92% less sodium. Hypoxibate sodium is approved for use in adult patients with idiopathic hypersomnia in the United States.
The researchers enrolled 154 patients with an average (SD) age of 40.3 (13.7) years, an average (SD) weight of 76.9 (18.7) kg at baseline, and an average (SD) obesity index (SD). Phase 3 clinical study was conducted. BMI) 27.1 (5.9) at baseline at kg / m2.2 To include, the patient must be 18-75 years old and has never been previously treated with oxybate sodium.
The patient started treatment with low sodium oxybate. Two weeks after a stable dosing period, patients were randomized to continue treatment or were given placebo for another two weeks followed by a 24-week open-label extension.
At baseline, 1.3% (n = 2) of patients are considered underweight, 40.3% (n = 62) are labeled as normal weight, and 33.8% (n = 52) are overweight, 24.7%. (N = 38) was overweight. Labeled as obese according to their BMI.
At the end of the stable dosing period, 28.7% (n = 31) of weight loss in at least 5% of patients. The average (SD) weight lost during the period was 2.5 (4.1) kg. Patients with high BMI at baseline had numerically greater mean weight loss.
Both studies were funded by Jazz Pharmaceuticals.
reference
- Davisdon R, Brattner M, Scammell T, Zhou E. Impact of idiopathic hypersomnia on social and romantic relationships in young adults. Announcement location: SLEEP 2022; June 5-8, 2022. Charlotte, North Carolina. Abstract 0416.
- Dauvilliers Y, Chandler P, Hickey L, Chen A, Steininger T, Foldvary-Shaefer N. Weight changes during treatment with oxybate hyposodium in a phase 3 clinical trial in patients with idiopathic hypersomnia. Announcement location: SLEEP 2022; June 5-8, 2022. Charlotte, North Carolina. Abstract 0387.
..
